Michael Weiss, TG Therapeutics CEO
January 27, 2022 01:50 PM ESTUpdated 02:01 PM
FDA+

Biotech gets burned at a fire­side chat as CEO re­veals FDA clamped a hold on its can­cer drug, now un­der re­view

John Carroll

Editor & Founder

A not-so-fun­ny thing hap­pened to TG Ther­a­peu­tics on its way to the ac­com­mo­da­tion re­view for its lead drug. The CEO re­vealed at an in­vest­ment con­fer­ence …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times